Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664252 | 0.92 | GRIK1 (0.70) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664245 | 0.89 | RAB9A (0.56) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664259 | 0.89 | GRIK1 (0.62) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664202 | 0.88 | MEN1 (0.60) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664251 | 0.86 | RXFP1 (0.61) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664309 | 0.85 | P2RX1 (0.60) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664286 | 0.85 | MEN1 (0.70) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664467 | 0.85 | RXFP1 (0.60) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664200 | 0.85 | KDR (0.64) | GRIK1MEN1MAPTHTTRAB9A | |
| SCHEMBL17664279 | 0.84 | P2RX1 (0.62) | GRIK1MEN1MAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-09-28 | — | — | US | disclosed |
| WO-2016049774-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | AR, UTS2R, SHBG | GRIK1 3740/4885MEN1 1148/4885MAPT 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.